Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results - Pavel, M; Ćwikła, JB; Lombard-Bohas, C (Eur J Cancer, 2021)
et al.